Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Opioid Use Disorder
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove People with Alcohol Use or Abuse Problems as Population Group
- Remove People with Co-Occurring Disorders
- Remove Buprenorphine
- Remove Prescription Drugs
- Remove Heroin
- Remove Opium
- Remove Medication-Assisted Treatment
- Remove Primary Care
- Remove Recovery
Main page content
Published: December 2021
This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: January 2021
The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).